PT1974017E - Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo - Google Patents

Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo Download PDF

Info

Publication number
PT1974017E
PT1974017E PT06824300T PT06824300T PT1974017E PT 1974017 E PT1974017 E PT 1974017E PT 06824300 T PT06824300 T PT 06824300T PT 06824300 T PT06824300 T PT 06824300T PT 1974017 E PT1974017 E PT 1974017E
Authority
PT
Portugal
Prior art keywords
influencing
stability
methods
producing cells
antibody producing
Prior art date
Application number
PT06824300T
Other languages
English (en)
Inventor
Hergen Spits
Ferenc Alexander Scheeren
Tim Beaumont
Sean Andrew Diehl
Original Assignee
Amc Amsterdam
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1974017(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2005/000848 external-priority patent/WO2007067032A1/en
Application filed by Amc Amsterdam, Aimm Therapeutics Bv filed Critical Amc Amsterdam
Publication of PT1974017E publication Critical patent/PT1974017E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT06824300T 2005-12-09 2006-12-08 Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo PT1974017E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2005/000848 WO2007067032A1 (en) 2005-12-09 2005-12-09 Means and methods for influencing the stability of cells
EP06076211 2006-06-12

Publications (1)

Publication Number Publication Date
PT1974017E true PT1974017E (pt) 2014-02-11

Family

ID=37714656

Family Applications (2)

Application Number Title Priority Date Filing Date
PT06824300T PT1974017E (pt) 2005-12-09 2006-12-08 Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo
PT121751986T PT2540820T (pt) 2005-12-09 2006-12-08 Meios e métodos para influenciar a establidade de células produtoras de anticorpos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT121751986T PT2540820T (pt) 2005-12-09 2006-12-08 Meios e métodos para influenciar a establidade de células produtoras de anticorpos

Country Status (14)

Country Link
US (3) US9127251B2 (pt)
EP (3) EP2540820B1 (pt)
JP (2) JP5753339B2 (pt)
AU (2) AU2006323315B2 (pt)
BR (2) BR122021001906B1 (pt)
CA (2) CA2633157C (pt)
DK (2) DK2540820T3 (pt)
ES (2) ES2660899T3 (pt)
FI (1) FI1974017T4 (pt)
HU (1) HUE037580T2 (pt)
NZ (3) NZ569543A (pt)
PL (2) PL2540820T3 (pt)
PT (2) PT1974017E (pt)
WO (1) WO2007067046A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
FI1974017T4 (fi) 2005-12-09 2023-09-14 Välineitä ja menetelmiä, joilla voidaan vaikuttaa vasta-ainetta tuottavien solujen stabiliteettiin
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP5205597B2 (ja) * 2007-06-01 2013-06-05 静岡県 １細胞レベルでの抗体遺伝子の解析・同定方法
US8715743B2 (en) 2007-08-03 2014-05-06 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2307453A1 (en) * 2008-06-16 2011-04-13 University Of Zurich Method of providing immunoglobulin secreting b lymphocytes and human antibodies
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
EP2646466B1 (en) 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
US9718874B2 (en) 2011-12-02 2017-08-01 Aimm Therapeutics B.V. Influenza A virus specific antibodies
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
KR20240042192A (ko) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
ES2927905T3 (es) * 2013-12-24 2022-11-11 Kling Biotherapeutics B V Producción de anticuerpos ex vivo
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
AU2015268982B2 (en) * 2014-06-05 2021-11-04 Kling Biotherapeutics B.V. Means and methods for determining T cell recognition
WO2016002760A1 (ja) 2014-07-02 2016-01-07 学校法人東京理科大学 Ｂ細胞集団の製造方法
PL3234107T3 (pl) * 2014-12-19 2023-01-16 Immusoft Corporation Limfocyty b do dostarczania in vivo środków terapeutycznych
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016201077A1 (en) 2015-06-12 2016-12-15 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
CN107810191B (zh) 2015-06-24 2023-06-13 科凌生物医疗有限公司 Aml抗原及其用途
EA201891299A1 (ru) 2016-01-08 2019-01-31 Аимм Терапьютикс Б.В. Терапевтические антитела к cd9
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3576758A4 (en) * 2017-01-31 2020-12-09 Vanderbilt University GENERATION OF IGE MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN ALLERGENS AND HELMINTHS FOR DIAGNOSTIC AND THERAPEUTIC USE
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CN111683964A (zh) * 2017-12-05 2020-09-18 Sqz生物技术公司 细胞内递送生物分子来调节抗体产生

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
JPH04501052A (ja) 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
ATE146819T1 (de) * 1992-10-05 1997-01-15 Hybridon Inc Therapeutisches anti-hiv oligonukleotid und arzneimittel
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) * 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1995006409A1 (en) 1993-09-03 1995-03-09 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
US6265556B1 (en) * 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
JP2003509025A (ja) * 1999-09-08 2003-03-11 ジーントロール バイオセラピューティクス， インコーポレイテッド 細胞生存能力が増強した高レベルサイトカイン産生
EP1083230A1 (en) 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) * 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
US20030152559A1 (en) * 2001-12-10 2003-08-14 Lili Yang Method for the generation of antigen-specific lymphocytes
SI1458855T1 (sl) * 2001-12-18 2012-08-31 Cancer Rec Tech Ltd Postopek za pripravo proliferacijskih in diferenciacijskih celičnih linij
CA2471392A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US20040248296A1 (en) 2002-03-20 2004-12-09 Beresford Paul J. HIV therapeutic
JP2004121237A (ja) * 2002-09-05 2004-04-22 Japan Science & Technology Agency 体外免疫末梢血リンパ球を用いた抗原特異的抗体
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
DE602004028280D1 (de) * 2003-11-19 2010-09-02 Us Gov Health & Human Serv Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b-zellen
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) * 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) * 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
US8337851B2 (en) 2005-05-18 2012-12-25 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
EP1891209A1 (en) 2005-06-06 2008-02-27 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for generating a t cell against an antigen of interest.
AU2006316288B2 (en) 2005-11-17 2012-12-20 Tet Systems Gmbh & Co. Kg Inducible expression systems
US9005974B2 (en) * 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
FI1974017T4 (fi) 2005-12-09 2023-09-14 Välineitä ja menetelmiä, joilla voidaan vaikuttaa vasta-ainetta tuottavien solujen stabiliteettiin
EP2126105A4 (en) * 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN102482639B (zh) * 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
HUE038277T2 (hu) 2009-07-15 2018-10-29 Aimm Therapeutics Bv Gram-pozitív baktériumokra specifikus kötõvegyületek
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
EP2646466B1 (en) 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
US9718874B2 (en) 2011-12-02 2017-08-01 Aimm Therapeutics B.V. Influenza A virus specific antibodies

Also Published As

Publication number Publication date
EP3327117A1 (en) 2018-05-30
ES2444465T5 (es) 2023-11-30
EP1974017B1 (en) 2013-11-06
EP2540820A1 (en) 2013-01-02
CA3015416C (en) 2022-10-11
AU2014202709A1 (en) 2014-06-12
NZ569543A (en) 2012-12-21
US20170306293A1 (en) 2017-10-26
PL2540820T3 (pl) 2018-05-30
ES2660899T3 (es) 2018-03-26
US9822339B2 (en) 2017-11-21
JP2009518033A (ja) 2009-05-07
BRPI0619579B8 (pt) 2022-01-25
US20160060598A1 (en) 2016-03-03
US9127251B2 (en) 2015-09-08
AU2006323315B2 (en) 2014-02-20
EP1974017B2 (en) 2023-06-21
NZ600075A (en) 2013-12-20
WO2007067046A1 (en) 2007-06-14
DK1974017T4 (da) 2023-09-25
PL1974017T5 (pl) 2023-10-23
AU2006323315A1 (en) 2007-06-14
AU2014202709B2 (en) 2016-09-08
FI1974017T4 (fi) 2023-09-14
DK1974017T3 (da) 2014-02-10
NZ592159A (en) 2012-12-21
JP5753339B2 (ja) 2015-07-22
CA3015416A1 (en) 2007-06-14
JP5753547B2 (ja) 2015-07-22
CA2633157C (en) 2018-10-09
EP2540820B1 (en) 2018-01-10
HUE037580T2 (hu) 2018-09-28
DK2540820T3 (en) 2018-03-12
CA2633157A1 (en) 2007-06-14
PT2540820T (pt) 2018-03-02
EP1974017A1 (en) 2008-10-01
US20100113745A1 (en) 2010-05-06
BRPI0619579B1 (pt) 2021-07-20
JP2013099358A (ja) 2013-05-23
US10273454B2 (en) 2019-04-30
PL1974017T3 (pl) 2014-04-30
ES2444465T3 (es) 2014-02-25
BR122021001906B1 (pt) 2022-03-29
BRPI0619579A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
PL1974017T5 (pl) Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała
IL190472A (en) Glyphican Antibody 3 Methods for their preparation and use
HK1211985A1 (en) Methods for the production of ansamitocins
HK1133441A1 (en) Anti-mn antibodies and methods of using same
GB0412973D0 (en) Identification of antibody producing cells
IL191820A0 (en) Anti-ox40l antibodies and methods using same
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
EP1915177A4 (en) ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
EP1885402A4 (en) ANTIBODIES AGAINST METAPNEUMOVIRUS FROM MAMMALS
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
GB0511976D0 (en) Methods and apparatus for the manufacture of microstructures
IL182940A0 (en) Solid electrolyte and method of producing the same
EP1743025A4 (en) METHOD OF MANUFACTURING REGULATOR T CELLS AND THEIR USE
EP1840084A4 (en) PROCESS FOR PRODUCING POROUS SILICA PARTICLES AND POROUS SILICA PARTICLES PRODUCED USING THE METHOD
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
IL177405A0 (en) Micro fuel cells and methods for the production thereof
EP2185718A4 (en) HUMAN MONOCLONAL ANTIBODIES AND METHOD FOR THEIR MANUFACTURE
GB0428136D0 (en) Novel materials and methods for the production thereof
ZA200704058B (en) Methods for producing mammalian cells
GB0428134D0 (en) Novel materials and methods for the production thereof
PL369540A1 (pl) Sposób wytwarzania symetrycznych mezo-tetraaryloporfiryn
PL376036A1 (pl) Sposób otrzymywania paliwa brykietowanego
PL376420A1 (pl) Nowa pochodna pirymidyny i sposób wytwarzania nowej pochodnej pirymidyny
GB0428133D0 (en) Novel materials and methods for the production thereof
PL375667A1 (pl) Ekologiczny brykiet opałowy i sposób wytwarzania ekologicznego brykietu opałowego